Urolithin B suppressed osteoclast activation and reduced bone loss of osteoporosis via inhibiting <scp>ERK</scp>/<scp>NF‐κB</scp> pathway

Abstract

Urolithin B attenuated bone loss in OVX mice by inhibiting the formation and activation of osteoclasts via down-regulation of the ERK/NF-κB signalling pathway.